medigraphic.com

2006, Number 1

<< Back Next >>

Cir Cir 2006; 74 (1)

Toxic epidermic necrolysis

Díaz DM, Moreno-Santillán AA, González-Díaz JI, Briones-Garduño JC

Language: Spanish
References: 19
Page: 37-40
PDF size: 86.84 Kb.


ABSTRACT

Background: Toxic epidermal necrolysis is a dermatological disease that evolves with an elevated mortality. Our objective was to show the utility of a nonconventional treatment for toxic epidermal necrolysis in place of conventional treatment where the mortality is >50 %. With this suggested treatment, mortality is 0 %.
Methods: This is a prospective and descriptive study presenting the case of 12 patients with toxic epidermal necrolysis. Diagnosis was made by history of drug ingestion, clinical presentation and skin biopsy, which was corroborated by light microscopy.
Results: Twelve patients were treated with heparin, dypiridamol, potassium permanganate, methylcellulose, respiratory therapy treatments and early peritoneal dialysis for stabilization in one patient who development acute renal failure. All patients recovered between 20 and 25 days after the beginning of the disease with a mortality of 0 %.
Conclusions: The relationship between intravascular coagulation and TEN is corroborated by mediators of the inflammatory reaction that can trigger multiple organ dysfunction. By using anticoagulants and antiplatelet drugs at an early stage, the inflammatory response can be avoided as demonstrated in our group of patients.


REFERENCES

  1. Brocq L, Gougerot D, Rabreu. Le pemphigus subaigu le mali a bulles extensives. Bull Franc Dermatol 1919;7:449-451.

  2. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956;68:355-361.

  3. Garnier G. Syndrome of Lyell. Press Med 1962;29:437-439.

  4. Lyell A, Dick HM, Alexander JOD. Outbreak of toxic epidermal necrolysis associated with staphylococci. Lancet 1969;1:787-791.

  5. Becker DS. Toxic epidermal necrolysis. Lancet 1998;351:1417-1420. 6.Wolkenstein P. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134(4):710-714.

  6. Paquet P, Nikkels A, Arrese JE, et al. Macrophages and tumor necrosis factor alfa in toxic epidermal necrolysis. Arch Dermatol 1994;130:605-608.

  7. Cohen JJ, Duke RC. Apoptosis and programmed cell death in immunity. Annu Rev Immunol 1992;10:267-293.

  8. Nassif A, Bensussan A, Boumsell L. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004;114:1209-1215.

  9. Shear N, Spielberg S, Grant D, Tang B, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986;105:179-184.

  10. Wolkenstein P, Charue D, Laurent P, Revuz J, Roujeau J, Bagot M. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 1955;131:544-551.

  11. Goodman H. Nikolsky sign. Arch Dermatol Syphilol 1953;68:334. 13.Revuz J, Penso D, Roujeau J, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-1165.

  12. McIvor R, Zaidi J, Peters W, Hyland R. Acute and chronic respiratory complications of toxic epidermal necrolysis. J Burn Care Rehabil 1996;17:237-240.

  13. Macotela-Ruiz E. Mendoza AG. Fraga MA. El síndrome de Brocq-Lyell (necrólisis epidérmica tóxica). Prensa Médica Méx 1964;193:7-8.

  14. Macotela-Ruiz E. González AM. Fraga MA. El síndrome de Brocq-Lyell. Med Cut 1966;5:453-456.

  15. Pizzuto J. Macotela-Ruiz E. Síndrome de hipercoagulabilidad en la necrólisis epidérmica tóxica (Brocq-Lyell). Memorias de la XI Jornada anual de la agrupación Mexicana para el estudio de la hematología; 1970.

  16. Díaz de León PM, González MA, Ramírez OH, Zurita CR, Rojas YE, Ronces VR. Necrólisis epidérmica tóxica. Avance terapéutico. Arch Invest Med 1973;2:152-158.

  17. Martínez SJ. Díaz de León PM. Profilaxis de la coagulación intravascular en la necrólisis epidérmica tóxica. Rev Med IMSS 1982;40:479-483.

  18. Díaz de León PM. Herrera RC. Cruz LC. Valor normal de la presión coloidosmótica en adultos sanos de la ciudad de México. Arch Invest Med 1981;12:307-321.

  19. Braunwald E, Fauci SA, Kasper LD, Hauser LS, Longo LD, Jameson LJ. Harrison Principios de Medicina Interna. España: McGraw-Hill Interamericana;2002. pp. 1056-1057.




2020     |     www.medigraphic.com